Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

NCT02205372 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Nephropathy

Interventions

DRUG: MT-3995
DRUG: Placebo

Sponsor

Tanabe Pharma Corporation